// Index Comparison
ACCE Biotech Catalysts vs ACCE Semiconductors
Head-to-head: performance, risk profile, and constituent overlap between two ACCE indices.
US
ACCE Biotech Catalysts →
Binary catalyst pipeline — FDA approvals, late-stage trial readouts, and M&A targets. High conviction names with visible catalysts.
US
ACCE Semiconductors →
The full semiconductor value chain — from chip design through fabrication to equipment. Cyclical upswing meets structural AI demand.
ACCE Biotech Catalysts — risk
Volatility 30d+21.6%
Volatility 90d+25.2%
Sharpe 90d-1.05
Max drawdown-13.4%
Beta vs SPY0.91
ACCE Semiconductors — risk
Volatility 30d+39.1%
Volatility 90d+36.9%
Sharpe 90d2.59
Max drawdown-13.9%
Beta vs SOXX2.09
Constituent overlap
0 stocks held by both indices (out of 6 and 11)
Top sectors — ACCE Biotech Catalysts
Healthcare100.0%
Top sectors — ACCE Semiconductors
Technology100.0%
ACCE Verdict
**ACCE Semiconductors has crushed ACCE Biotech Catalysts since inception, delivering 33.28% returns versus biotech's -7.6% loss.** Both strategies significantly outpaced and underperformed the benchmark's 4.74% return respectively.
The risk profiles tell contrasting stories: semiconductors run much hotter with 36.9% volatility but compensate with a stellar 2.59 Sharpe ratio, while biotech's 25.2% volatility paired with a -1.05 Sharpe ratio reflects pure pain without reward.
These indices share virtually nothing beyond their thematic focus on innovation sectors. Biotech targets binary FDA catalysts and M&A plays, while semiconductors captures the full chip value chain riding both cyclical recovery and structural AI demand.
**Semiconductors suits aggressive growth investors willing to stomach 2.09 beta exposure for outsized returns in a proven secular trend.** The combination of strong Sharpe ratio and manageable 13.9% max drawdown suggests the volatility has been rewarded. Biotech Catalysts appeals to contrarian investors betting on a sector rotation into beaten-down names with visible catalysts, but the current risk-reward profile offers little justification beyond pure speculation on timing a biotech recovery.